Safety of the cardiac triple therapy: The experience of the Quebec Heart Institute

Brulotte, Steeve; Sénéchal, Mario; Poirier, Paul; Lemieux, Ariane; Magné, Julien; Bergeron, Sébastien

doi:10.1016/s0828-282x(07)71016-4

Cited by 2 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reported increase in efficacy however, comes at the price of an increased risk of major bleeding [8,9]. Rather consistently, albeit again not univocally, the relative risk (RR) of major bleeding has been shown to be approximately 2.5 fold that of DAPT [10][11][12][13][14][15][16][17][18] ( Table 2).…”

Section: Considerations On Available Evidencementioning

confidence: 99%

New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint

Rubboli¹,

Agewall²,

Huber³

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

The antithrombotic management of patients on oral anticoagulation (OAC), with either warfarin or non-vitamin K-antagonist oral anticoagulants (NOACs), undergoing percutaneous coronary intervention with stent (PCI-S) has been recently addressed in a joint European consensus document. In accordance, triple therapy (TT) of OAC, aspirin and clopidogrel should generally be given as the initial therapy. More uncertainty exists over whether warfarin or a NOAC should be added in patients already on dual antiplatelet therapy of aspirin and clopidogrel (DAPT) after recent PCI-S. Upon review of available data, it appears that the risk of major bleeding of TT as compared to DAPT is similar with either warfarin or a NOAC. In particular, TT consistently appears associated to an approximately 2.5 fold increase in the risk of major bleeding. Because of the higher convenience, NOACs might be considered the preferred OAC to be added to DAPT. Given the reported different safety profiles of the various NOACs on the incidence of major, and gastrointestinal, bleeding, the NOACs, and the dose, showing the greatest safety in this regard should be selected. In accordance, dabigatran 110 mg and apixaban 2.5mg twice daily appear as the most valuable options in patients who are not and who are respectively, at increased risk of bleeding. As an alternative, apixaban 5mg twice daily might be considered in patients at risk of bleeding not increased, whereas rivaroxaban 15 mg once daily may be considered in the presence of increased risk of bleeding (essentially when related to moderate renal impairment).

show abstract